Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

Mehdi Hamadani, Maud Ngoya, Anna Sureda, Qaiser Bashir, Carlos Alejandro Litovich, Herve Finel, Yue Chen, Ariane Boumendil, Jasmine Zain, Luca Castagna, Amanda F. Cashen, Didier Blaise, Mazyar Shadman, Rocco Pastano, Farhad Khimani, Mutlu Arat, Sascha Dietrich, Norbert Schmitz, Bertram Glass, Mohamed A. Kharfan-DabajaPaolo Corradini, Craig S. Sauter, Silvia Montoto, Mi Kwon, Alex F. Herrera, Peter Dreger

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Mature T-cell lymphomas constitute the most common indication for allogeneic hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies evaluating contemporary outcomes of allo-HCT in mature T-cell lymphomas relative to commonly used donor sources are not available. Included in this registry study were adult patients who had undergone allo-HCT for anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) between 2008 and 2018. Hematopoietic cell transplantation (HCT) platforms compared were posttransplant cyclophosphamide-based haploidentical (haplo-)HCT, matched sibling donor (MSD) HCT, matched unrelated donor HCT with in vivo T-cell depletion (MUD TCD1), and matched unrelated donor HCT without in vivo T-cell depletion (MUD TCD2). Coprimary end points were overall survival (OS) and progression-free survival (PFS); secondary end points included nonrelapse mortality (NRM), and relapse/progression incidence (RI). A total of 1942 patients were eligible (237 haplo-HCT; 911 MSD; 468 MUD TCD1; 326 MUD TCD2). Cohorts were comparable for baseline characteristics with the exception of higher proportions of patients with decreased performance status (PS) and marrow graft recipients in the haplo-HCT group.

Original languageEnglish
Pages (from-to)920-930
Number of pages11
JournalBlood Advances
Issue number3
StatePublished - Feb 8 2022


Dive into the research topics of 'Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics'. Together they form a unique fingerprint.

Cite this